Insmed To Present at the BofA Securities Health Care Conference 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Insmed (INSM) PT Raised to $43 at Morgan Stanley
May 9, 2024 12:11 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $43.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "Insmed reported 1Q Arikayce sales of $75.5M (consensus: $78M) and reiterated guidance 2024 Arikayce revenue guidance of $340M-360M. The company... More
